AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO
- Outstanding scientist and entrepreneur Dr. Madiha Derouazi appointed as new CSO
- Retiring CSO Dr.
Marie Kosco-Vilbois will remain as consultant to ensure smooth handover - Christopher Roberts, Interim Chief Financial Officer, confirmed in role on a permanent basis
Lausanne,
Dr. Madiha Derouazi, an accomplished immunologist, joins from Speransa Therapeutics where she had been CEO since inception in 2021, leading development of a novel platform of prophylactic vaccines. Previously, she founded
Christopher Roberts joined
Dr.
“I would like to take this opportunity to warmly thank Marie for her dedicated service to
About
AC Immune SA is a clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen® and Morphomer®, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features ten therapeutic and three diagnostic candidates, five of which are currently in Phase 2 clinical trials and one of which is in Phase 3. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies including Genentech, a member of the Roche Group, Eli Lilly and Company, and others, resulting in substantial non-dilutive funding to advance its proprietary programs and >$3 billion in potential milestone payments.
SupraAntigen® is a registered trademark of AC Immune SA in the following territories: AU, EU, CH, GB, JP, RU, SG and USA. Morphomer® is a registered trademark of AC Immune SA in CN, CH, GB, JP, KR, NO and RU.
The information on our website and any other websites referenced herein is expressly not incorporated by reference into, and does not constitute a part of, this press release.
For further information, please contact:
Head of Investor Relations & Corporate Communications Phone: +41 21 345 91 91 Email: gary.waanders@acimmune.com | U.S. Investors Phone: +1 212 915 2577 Email: cdavis@lifesciadvisors.com | |
International Media Phone: +41 79 367 6254 Email: chris.maggos@cohesionbureau.com |
Forward looking statements
This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the
Attachments
- 20231201_ACIU_Management change-FINAL
AC Immune appoints Madiha Derouazi as CSOAC Immune appoints Christopher Roberts as CFO
![](https://ml-eu.globenewswire.com/media/NzFiZDZjOTItODc0OS00YzgwLWI1OGEtNTFhOTEyZTM5YTVlLTEwMzc0NDM=/tiny/AC-Immune-SA.png)
AC Immune appoints Madiha Derouazi as CSO
![](https://ml-eu.globenewswire.com/media/5fab6be2-0221-4868-a33a-37ad968a58be/medium/ac-immune-appoints-madiha-derouazi-as-cso.jpeg)
Dr. Madiha Derouazi appointed as new CSO of AC Immune
AC Immune appoints Christopher Roberts as CFO
![](https://ml-eu.globenewswire.com/media/ea24f53b-1293-4085-ada5-a65b3c5a26d6/medium/ac-immune-appoints-christopher-roberts-as-cfo.jpeg)
Christopher Roberts confirmed in CFO role on a permanent basis
2023 GlobeNewswire, Inc., source